Merck & Co., Inc.
General ticker "MRK" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $233.8B (TTM average)
Merck & Co., Inc. follows the US Stock Market performance with the rate: 42.4%.
Estimated limits based on current volatility of 1.7%: low 114.90$, high 118.94$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-03-16, amount 0.85$ (Y2.96%)
- Total employees count: 75000 as of 2025
- US accounted for 50.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Patent expiration, R&D failure, Pricing pressure, Market competition, Regulatory and compliance
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [74.98$, 110.88$]
- 2026-12-31 to 2027-12-31 estimated range: [85.43$, 123.32$]
Financial Metrics affecting the MRK estimates:
- Negative: with PPE of 11.6 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 36.17 > 18.39
- Positive: 19.24 < Shareholder equity ratio, % of 38.44 <= 42.59
- Positive: Interest expense per share per price, % of 0.52 <= 0.73
- Positive: Return on assets ratio (scaled to [-100,100]) of 11.77 > 6.06
- Positive: -0.02 < Operating cash flow per share per price, % of 6.32
- Positive: Industry earnings per price (median), % of 5.49 > 4.45
- Positive: Industry inventory ratio change (median), % of 0.28 <= 0.28
- Positive: Inventory ratio change, % of 0.61 <= 0.78
Short-term MRK quotes
Relationship graph
Long-term MRK plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $60,115.00MM | $64,168.00MM | $64,926.00MM |
| Operating Expenses | $57,161.00MM | $43,947.00MM | $41,440.00MM |
| Operating Income | $2,954.00MM | $20,221.00MM | $23,486.00MM |
| Non-Operating Income | $-1,065.00MM | $-285.00MM | $-2,419.00MM |
| Interest Expense | $1,146.00MM | $1,271.00MM | $1,357.00MM |
| R&D Expense | $30,531.00MM | $17,938.00MM | $12,514.00MM |
| Income(Loss) | $1,889.00MM | $19,936.00MM | $21,067.00MM |
| Taxes | $1,512.00MM | $2,803.00MM | $2,804.00MM |
| Net Income(Loss)* | $365.00MM | $17,117.00MM | $18,254.00MM |
| Stockholders Equity | $37,581.00MM | $46,313.00MM | $52,606.00MM |
| Inventory | $6,358.00MM | $6,109.00MM | $6,658.00MM |
| Assets | $106,675.00MM | $117,106.00MM | $136,866.00MM |
| Operating Cash Flow | $13,006.00MM | $21,468.00MM | $16,472.00MM |
| Capital expenditure | $3,863.00MM | $3,372.00MM | $4,112.00MM |
| Investing Cash Flow | $-14,083.00MM | $-7,734.00MM | $-13,741.00MM |
| Financing Cash Flow | $-4,810.00MM | $-7,032.00MM | $-1,922.00MM |
| Earnings Per Share** | $0.14 | $6.76 | $7.30 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.